Lapachol Extract.

Lapachol is a naphthoquinone closely related in structure to vitamin K and can act against vitamin K dependent gamma-carboxylation of clotting factors. Taken together the two work in opposite directions at the same enzyme step.

Menaquinone shares the naphthoquinone core that lapachol mimics, so lapachol can compete with it at the vitamin K epoxide cycle. That opposes the carboxylation reactions menaquinone is taken for.

Lapachol interferes with vitamin K dependent clotting factor activation while EPA shifts platelet eicosanoid balance toward less aggregation. The two effects stack on normal clotting from different directions.

Nattokinase acts on fibrin while lapachol works against vitamin K dependent factor carboxylation. Combining them adds two independent brakes on the same clotting cascade.

Ginkgolides antagonise platelet activating factor while lapachol works against vitamin K dependent clotting factors. The effects are additive because they sit on different steps of haemostasis.

Garlic organosulfur compounds reduce platelet aggregation, and lapachol acts against the vitamin K arm. Together they lean on normal clotting more than either alone.

Naphthoquinones such as lapachol are handled by glutathione conjugation and can draw down the reduced glutathione pool during redox cycling. Glutathione status therefore shapes how the compound is cleared.

NAC supplies the rate-limiting cysteine for glutathione synthesis, the conjugation route that handles quinone metabolites. It supports the pathway lapachol draws on.

Curcuminoids inhibit platelet aggregation in laboratory preparations, and naphthoquinones with vitamin K-like structure interact with clotting-factor chemistry. Stacking two inputs that both act on clot formation is a directional interaction worth disclosing, not a benefit. Anyone on blood-thinning medication should raise the combination with their clinician.

Willow bark supplies salicin, which is converted to salicylate and reduces platelet aggregation by an established mechanism. Combining it with a naphthoquinone that engages vitamin K-dependent chemistry pushes the same direction. Flag the pairing rather than recommend it.

Proteolytic activity from bromelain has been described as affecting fibrin handling and platelet behaviour in laboratory work. The human magnitude is not well quantified. Together with lapachol the interaction is worth naming for disclosure, and the confidence stays low.

Alpha-tocopherol at high intake antagonises vitamin K function and reduces platelet aggregation, two established pharmacological effects. A naphthoquinone that resembles vitamin K structurally sits on the same axis. Report the overlap; do not present it as a formulation advantage.

Lapachol is a hydroxy-naphthoquinone, a chemical class that cycles between quinone and semiquinone states and generates superoxide in the process. Iron drives Fenton chemistry downstream of that superoxide, which is textbook inorganic biochemistry. The consequence in a person taking both has not been measured, so this is a mechanism to disclose rather than an outcome.

Copper cycles between two oxidation states and can accelerate radical chemistry from quinone autoxidation in vitro. No human co-administration data exists. The row is here so a formulator sees the chemistry, not because a benefit was shown.

Glutathione peroxidase activity depends on selenocysteine, so selenium status sets part of the cell's capacity to handle hydrogen peroxide. Quinone cycling raises peroxide load in laboratory systems. The connection is established biochemistry at the enzyme level and untested as a supplement pairing.

Dihydrolipoate can reduce quinones directly, which changes the balance between the quinone and semiquinone forms. That shift can either damp or sustain cycling depending on oxygen availability. Direction is not predictable from chemistry alone, so the row is labelled modulating.

Quercetin and naphthoquinones are both substrates for glucuronidation, sulfation and glutathione conjugation. Loading two substrates onto the same conjugation enzymes can change how quickly either clears. This is pathway-level reasoning, not a measured pharmacokinetic interaction.

Flavonolignans from milk thistle influence glucuronidation and glutathione handling in preclinical systems, the same routes that clear naphthoquinone metabolites. Whether that raises or lowers lapachol exposure has not been measured in people. Keep the claim at mechanism level.